Neurogene Reports Serious Adverse Event in Phase 1/2 Rett Study of Gene Therapy NGN-401

Published Date: 21 Nov 2024

The company has decided to pause enrollment in the high-dose cohort of its phase 1 clinical trial for NGN-401 after a participant experienced a serious treatment-related adverse event.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Newly identified T-cell subtype may explain treatment-resistant childhood leukemia

2.

Glioblastoma treatment breakthrough shows promise

3.

A computer-aided diagnostic system for improved detection of breast cancer.

4.

Patients With Melanoma Brain Mets May Fare Better With RT Before Immunotherapy

5.

Browse the NBE-Released Curriculum at FNB Head and Neck Oncology.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot